First Eagle Investment Management Adds $567M in Waters Corporation ($WAT)

Key Points

  • Wall Street's consensus rating on $WAT is Buy and an average price target of $400.27.
  • $WAT last traded around $359.74.

First Eagle Investment Management acquired a new position in Waters Corporation ($WAT), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,575,187 shares of Waters Corporation. First Eagle Investment Management's holdings in Waters Corporation were worth $566.66 million as of its most recent filing.

Waters Corporation ($WAT) Stock

Last price$359.74
Market cap$34.91B
P/E ratio45.23
Forward P/E21.60
PEG ratio1.58
Beta1.20
52-week low$275.05
52-week high$414.15
50-day MA$336.78
200-day MA$343.61
Current ratio1.79
Quick ratio0.97
Debt-to-equity0.37

Waters Corporation Earnings

EPS (ttm)$7.86
Revenue (ttm)$3.77B
Revenue growth91.4%
Net margin11.9%
Return on equity5.2%
Next earningsJul 29, 2026

Analysts Set New Price Targets

ConsensusBuy
Average target$400.27
High target$460.00
Low target$345.00
Analysts covering22

About Waters Corporation

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

ExchangeNYSE
SectorHealthcare
IndustryDiagnostics & Research
HeadquartersMilford, MA
CEODr. Udit Batra Ph.D.
Employees16,000

See Also

This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.